SEARCH

SEARCH BY CITATION

References

  • 1
    Strahl S, Ehret V, Dahm HH, Maier KP. Necrotising hepatitis after taking herbal remedies. Dtsch Med Wschr 1998; 123: 14104. (in German).
  • 2
    Schmidt M, Morgan M, Bone K, McMillan J. Kava: a risk–benefit assessment. In: MillsM, BoneK, eds. The essential guide to herbal safety. St Louis, MO): Elsevier Churchill Livingstone, 2005; 155221.
  • 3
    Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003; 10: 4406.
  • 4
    Denham A, McIntyre M, Whitehouse J. Kava – the unfolding story: report on a work-in-progress. J Altern Complement Med 2002; 8: 23763.
  • 5
    BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany). Rejection of Drug Risks, Step II. As related to: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. 14 June 2002. Available at http://www.spc.int/cis/documents/02_0714_BfArM_Kava_Removal.pdf (accessed 18 May 2010).
  • 6
    Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 118293.
  • 7
    Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 2009; 123: 37884.
  • 8
    Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 2002; 25: 25161.
  • 9
    Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions- a case study. Phytomedicine 2003; 10 (Suppl. IV): 6873.
  • 10
    Loew D, Franz G. Quality aspects of traditional and industrial kava-extracts. Phytomedicine 2003; 10: 6102.
  • 11
    Moulds RFW, Malani J. Kava: herbal panacea or liver poison? Med J Aust 2003; 178: 4513.
  • 12
    Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane Review). In: Cochrane Library, Issue I, 2003 Oxford: Update Software.
  • 13
    Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004; 150: 8596.
  • 14
    Ernst E. A re-evaluation of kava (Piper methysticum). Br J Clin Pharmacol 2007; 64: 4157.
  • 15
    Sarris J, Adams J, Wardle JL. Editorial: time for a reassessment of the use of kava in anxiety? Complement Ther Med 2009; 17: 1212.
  • 16
    World Health Organization. Assessments of the risk of hepatotoxicity with kava products. Geneva, Switzerland: WHO Document Production Services, 2007.
  • 17
    Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. New Zeal Med J 2008; 121: 1283 Available at http://www.nzma.org.nz/journal/121-1283/3296/ (accessed 18 May 2010).
  • 18
    Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liv Dis 2009; 41: 891901.
  • 19
    Teschke R. Kava hepatotoxicity – a clinical review. Ann Hepatol 2010; 9: in press.
  • 20
    Teschke R, Fuchs J, Bahre R, Genthner A, Wolff A. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J Clin Pharm Ther 2010; 34: in press. DOI: DOI: 10.1111/j.1365-2710.2009.01131.x.
  • 21
    Lebot V, Merlin M, Lindstrom L. Kava, the Pacific elixir. New Haven: Yale University Press, 1997.
  • 22
    Singh YH. Kava: an overview. J Ethnopharmacol 1992; 37: 1345.
  • 23
    Lebot V. The quality of kava consumed in the South Pacific. Herbal Gram 2006; 71: 347.
  • 24
    Singh YH. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005; 100: 10813.
  • 25
    Schmidt M. Quality criteria for kava. HerbalGram 2007; 73: 459.
  • 26
    Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. Ann Hepatol 2009; 8: 18495.
  • 27
    Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Brit J Clin Pharmacol 2008; 66: 75866.
  • 28
    Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by cimicifugae racemosae rhizoma (black cohosh, root): critical analysis and structured causality assessment. Phytomedicine 2009; 16: 7284.
  • 29
    Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009; 16: 95665.
  • 30
    Teschke R. Black cohosh and suspected hepatotoxicity – inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm: a critical review. Menopause 2010; 17: 42640.
  • 31
    Teschke R. Letter to the editor. Menopause 2010. DOI: DOI: 10.1097/gme.0b013e3181e32349. [Epub ahead of print].
  • 32
    Ernst E. Kava update: a European perspective. New Zeal Med J 2004; 117: 1205. Available at http://www.nzma.org.nz/journal/117-1205/1143/ (accessed 18 May 2010).
  • 33
    Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava. J Toxicol/Clin Toxicol 2003; 41: 10913.
  • 34
    De Abajo FJ, Montero D, Madurga M, Rodriguez LAG. Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br J Clin Pharmacol 2004; 58: 7180.
  • 35
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 48797.
  • 36
    Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006; 333: 158.
  • 37
    Currie BJ, Clough AR. Kava hepatotoxicity with Western herbal products: does it occur with traditional kava use? Med J Aust 2003; 178: 4212.
  • 38
    Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148: 54855.
  • 39
    Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol/Clin Toxicol 2003; 41: 8219.
  • 40
    Russmann S, Barguil Y, Cabalion P, et al. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 2003; 15: 10336.
  • 41
    Bujanda L, Palacios A, Silvariño R, Sánchez A, Muñoz C. Hepatitis aguda icterica secundaria a kava. Gastroenterol Hepatol 2002; 25: 4345.
  • 42
    Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther 2004; 3: 12848.
  • 43
    Amorim MFD, Diniz MFFM, Araújo MST, et al. The controvertible role of kava (Piper methysticum G. Forster) an anxiolytic herb, on toxic hepatitis. Rev Bras Farmacogn 2007; 17: 44854.
  • 44
    Ulbricht C, Basch E, Boon H, et al. Safety review of kava (Piper methysicum) by the Natural Standard Research Collaboration. Exp Opin Drug Saf 2005; 4: 77994.
  • 45
    Lüde S, Török M, Dieterle S, et al. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 2008; 15: 12013.
  • 46
    Xuan TD, Fukuta AA, Wie AC, et al. Efficacy of extracting solvents to chemical compounds of kava (Piper methysticum) root. J Nat Med 2008; 62: 18894.
  • 47
    DiSilvestro RA, Zhang W, DiSilvestro DJ. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. Food Chem Toxicol 2007; 45: 1293300.
  • 48
    Schmidt M. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory. Letter to the Editor. J Altern Complement Med 2003; 9: 1838.
  • 49
    Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and kava kava controversy. Phytochem 2003; 64: 6739.
  • 50
    Wu D, Yu L, Nair MG, DeWitt DL, Ramsewak RS. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots. Phytomedicine 2002; 9: 417.
  • 51
    Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2006; 34: 2037.
  • 52
    Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002; 30: 11537.
  • 53
    Zou L, Harkey MR, Henderson GL, Dike LE. Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med 2004; 70: 28992.
  • 54
    Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes. Clin Pharmacol Ther 2005; 77: 41526.
  • 55
    Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol 2004; 93: 15360.
  • 56
    Hu Z, Yang X, Ho PCL, et al. Herb–drug interactions. A literature review. Drugs 2005; 65: 123982.
  • 57
    Guo L, Li Q, Xia Q, et al. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol 2009; 47: 43342.
  • 58
    Mathews JM, Etheridge AS, Valentine JL, et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 2005; 33: 155563.
  • 59
    Guo L, Shi Q, Dial S, et al. Gen expression profiling in male B6C3F1 mouse livers exposed to kava identifies – Changes in drug-metabolizing genes and potential mechanism linked to kava toxicity. Food Chem Toxicol 2010; 48: 6886696.
  • 60
    Li XZ, Ramzan I. Role of ethanol in kava hepatotoxicity. Phytother Res 2010; 24: 47580.
  • 61
    Dragull K, Yoshida WY, Tang CS. Piperidine alkaloids from Piper methysticum. Phytochemistry 2003; 63: 1938.
  • 62
    Lechtenberg M, Quandt B, Schmidt M, Nahrstedt A. Is the alkaloid pipermethystine connected with the claimed liver toxicity of kava products? Pharmazie 2008; 63: 714.
  • 63
    Lim ST, Dragull K, Tang CS, et al. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci 2007; 97: 21421.
  • 64
    Nerurkar PV, Dragull K, Tang CS. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol Sci 2004; 79: 10611.
  • 65
    Jhoo JW, Freeman JP, Heinze TM, et al. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum). J Agric Food Chem 2006; 54: 315762.
  • 66
    Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 689.
  • 67
    Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178: 4424.
  • 68
    Weise B, Wiese M, Plötner A, Ruf BR. Toxic hepatitis after intake of kava-kava. Verdauungskrankheiten 2002; 4: 1669 (in German).
  • 69
    Secretariat of the Pacific Community. SPC Report. Pacific kava: a producer's guide. ISBN 982-203-810-0. Suva, Fiji Islands: Secretariat of the Pacific Community, 2001.
  • 70
    BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany), 12 May 2005. Available at http://www.bfarm.de/cln_028/nn_1198756/SharedDocs/Publikationen/DE/Pharmakovigilanz/stufenplverf/kava__bescheid__050517,templateId=raw,property=publicationFile.pdf/kava_bescheid_050517.pdf (accessed 18 May 2010).
  • 71
    Food standards Australia and New Zealand Kava. A human health risk assessment. Technical report Series No. 30, 2005. Food standards Australia and New Zealand Available at http://www.foodstandards.gov.au/_srcfiles/30_Kava.pdf (accessed 18 May 2010).
  • 72
    Brown AC, Onopa JO, Holck P, et al. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol 2007; 45: 54956.
  • 73
    Commission E of BGA/BfArM, 1990. Monographie Piperis methystici rhizoma (Kava-Kava-Wurzelstock). Bundesanzeiger Nr. 101; dated 1 June 1990.
  • 74
    Deutscher Arzneimittel-Codex (DAC). Kava-Kava-Wurzelstock: Piperis methystici rhizoma. Official monograph, 1998, Govi-Verlag, Eschborn (Germany).
  • 75
    Teschke R, Hasumura Y, Joly JG, Ishii H, Lieber CS. Microsomal ethanol-oxidizing system (MEOS): purification and properties of a rat liver system free of catalase and alcohol dehydrogenase. Biochem Biophys Res Commun 1972; 49: 118793.
  • 76
    Teschke R, Hasumura Y, Lieber CS. Hepatic microsomal alcohol-oxidizing system: affinity for methanol, ethanol, propanol and butanol. J Biol Chem 1975; 250: 7397404.
  • 77
    Teschke R, Gellert J. Hepatic microsomal ethanol-oxidizing system (MEOS): metabolic aspects and clinical implications. Alcoholism. Clin Exp Res 1986; 10 (Suppl.): 2032.
  • 78
    Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 51744.
  • 79
    Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJ. Identification of some human urinary metabolites of the intoxicating beverage kava. J Chromatogr 1989; 475: 27381.
  • 80
    Stickel F, Baumüller HM, Seitz K, et al. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 627.
  • 81
    Zimmerman HJ. Hepatotoxicity. Philadelphia: Lippincott Williams & Wilkins, 1999.
  • 82
    Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology 2009; 205: 399407.
  • 83
    Lasme P, Davrieux F, Montet D, Lebot V. Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in Vanuatu. J Agric Food Chem 2008; 56: 497681.